At what enterprise value was EMSERE acquired in 2026?

You can find the full valuation details of EMSERE on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of EMSERE when it was acquired by ANTIN INFRASTRUCTURE?

The exact EV/EBITDA multiple for EMSERE is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was EMSERE acquired by ANTIN INFRASTRUCTURE?

EMSERE was acquired by ANTIN INFRASTRUCTURE in 2026.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the EMSERE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the EMSERE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.antin-ip.com/media/our-news/antin-to-acquire-emsere-a-global-leader-in-clinical-trial-equipment-infrastructure

← DATABASE

Home Database Healthcare & PharmaEMSERE

01/2026

ANTIN INFRASTRUCTURE takes majority stake in EMSERE

NETHERLANDS Healthcare Services / CRO / Clinical Trials REV 1m EUR - 100m EUR

Context

Antin Infrastructure Partners, executing through its Mid Cap Fund I, has entered into a definitive agreement with Dutch family office and investment platform Gryphion to acquire 100% of Emsere. The transaction, which represents the eighth investment completed by Antin's dedicated mid-cap vehicle, is scheduled to close in the first quarter of 2026. The corporate buyouts' advisory perimeter included Macquarie as financial adviser and Loyens & Loeff as legal adviser to Antin, while Gryphion was backed by Moelis as financial adviser and DLA Piper as legal adviser. The acquisition thesis frames the clinical trial equipment rental space as an institutional healthcare infrastructure play, characterized by favorable long-term macroeconomic trends and high structural barriers to entry. The strategic rationale centers on capitalizing on the rapid growth of innovative clinical research endpoints, which drive outsourcing demands and require highly complex, specialized medical equipment and lifecycle service solutions.

EMSERE, which reported an EBITDA margin of LOGIN in 2026, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Emsere is a global leader in clinical trial equipment rental, providing mission-critical medical equipment and specialized logistics solutions for contract research organizations and pharmaceutical companies worldwide. Founded in 1996, Emsere is headquartered in Leiden, the Netherlands, and offers a comprehensive range of medical equipment, including centrifuges, vital signs devices, cardiovascular and respiratory monitoring machines, imaging devices, and cardio-pulmonary exercise testing equipment. With over 13,000 pieces of equipment in its portfolio, Emsere delivers to over 100 countries through its own distribution centers and third-party relationships, making it a globally consolidated solution for all clinical trial equipment needs. Emsere's customers include six of the top 10 global pharmaceutical companies and seven of the top 10 contract research organizations globally. Emsere is well-positioned in the fast-growing clinical trial equipment rental market, which continues to expand driven by increasing demand for outsourcing and the growing need for more complex equipment and service solutions to keep pace with innovative and evolving clinical research endpoints.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2026

2025

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
03/2026	RADNET	GLEAMER	FRANCE	Healthcare Services	RadNet acquired Gleamer in an all-cash transaction to integrate its automated diagnostic and reporting solutions into the DeepHealth platform. The acquisition aims to create the world's largest provider of clinical radiology AI solutions by combining RadNet's massive US imaging volume with Gleamer's advanced multi-modality software
03/2026	THERMO FISHER SCIENTIFIC	CLARIO HOLDINGS	UNITED STATES	Healthcare Services	Thermo Fisher Scientific has finalized the acquisition of Clario Holdings, Inc. from a prominent shareholder consortium led by Astorg, Nordic Capital, Novo Holdings, and Cinven. The strategic rationale for this transaction centers on the deep integration of the target's industry-leading endpoint data platform into the group's Laboratory Products and Biopharma Services segment
01/2026	PERMIRA	CARNE GROUP	IRELAND	Healthcare Services	Permira has reached an agreement to acquire a significant minority stake in Carne Group. The transaction facilitates the complete exit of Vitruvian Partners (who invested in 2021) and other minority shareholders
01/2026	TPG	OPTUM UK	UNITED KINGDOM	Healthcare Services	TPG is in advanced negotiations to acquire Optum UK from UnitedHealth Group. This transaction follows UnitedHealth’s relatively short ownership of the asset, which it acquired in 2023 after an intensive regulatory review by the UK Competition and Markets Authority
01/2026	SAGARD	QUIPMENT	FRANCE	Healthcare Services	Sagard NewGen acquired a significant minority stake in Quipment, fifteen years after its inception. The deal aims to accelerate Quipment's international expansion, particularly in the US and Asia, and to support its digital transformation
11/2025	EURAZEO	EXCELYA	FRANCE	Healthcare Services	The management team of Excelya selected Eurazeo to invest as a minority partner with a ticket composed of a mix of equity (capped at 20%) and quasi-equity instruments, alongside a senior debt package. The transaction facilitated a partial liquidity event for the co-founding partner, who remains a minority shareholder, while providing the company with substantial firepower to pursue further international acquisitions
11/2025	ASKER HEALTHCARE GROUP	FINMED GROUP	FRANCE	Healthcare Services	Asker Healthcare Group has signed a definitive agreement to acquire 80% of the shares in Finmed Group, marking its strategic entry into the French healthcare market. This transaction serves as a platform acquisition, providing the Swedish-based group with a robust foundation to expand its presence in one of Europe's largest medical device markets
10/2025	EVOLEM	APPERTON	FRANCE	Healthcare Services	A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates
05/2025	FIVE ARROWS	HUBLO	FRANCE	Healthcare Services	Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe
04/2025	TRANSCARENT	ACCOLADE	UNITED STATES	Healthcare Services	Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group

REFERENCES

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EMSERE by ANTIN INFRASTRUCTURE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: emsere

Acquirer: antin infrastructure